AnaptysBio (ANAB) Earnings Analysis
AnaptysBio (ANAB) has no confirmed upcoming earnings date. Last quarter (2026-03-03) it beat with EPS 1.58 USD vs 0.89 USD est (+77.5%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -61.89.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ANAB next report earnings?
No confirmed upcoming earnings date is currently scheduled for ANAB. This page updates as the calendar is published.
ANAB earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-03 | 1.58 USD | 0.89 USD | +77.5% | Beat |
| 2025-08-07 | -1.34 USD | -1.5 USD | +10.7% | Beat |
| 2025-05-05 | -1.28 USD | -1.3 USD | +1.5% | Beat |
| 2025-02-27 | -0.72 USD | -1.55 USD | +53.5% | Beat |
| 2024-11-04 | -1.14 USD | -1.72 USD | +33.7% | Beat |
| 2024-08-05 | -1.71 USD | -1.2 USD | -42.5% | Miss |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
ANAB valuation and analyst view
| Trailing P/E | -61.89 |
|---|---|
| Trailing EPS | -0.93364 USD |
| Price / book | 118.41 |
| Dividend yield | 0.00% |
| Market cap | 2.26B |
| Analyst consensus | Buy (16 buy / 6 hold / 0 sell) |
| Avg price target | 81.5 USD |
Related research pages
Frequently asked questions
When is AnaptysBio (ANAB)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ANAB. This page updates as the calendar is published.
Did ANAB beat earnings last quarter?
In its 2026-03-03 report, ANAB posted EPS of 1.58 USD versus a 0.89 USD estimate — a beat of 77.5%.
What is ANAB's earnings track record?
Over the last 6 reported quarters with consensus data, ANAB beat estimates 5 times (83%).
What is ANAB's current P/E ratio and EPS?
ANAB trades at a trailing P/E of -61.89 on trailing EPS of -0.9336377261162037 USD.
What do analysts rate ANAB?
Analyst consensus is "Buy" across 22 ratings (0 strong buy, 16 buy, 6 hold, 0 sell, 0 strong sell). Average 12-month price target: 81.5 USD.